Medical experts discuss the evolving treatment landscape and adverse events associated with 3L colorectal cancer treatment.
Funding supported by Taiho Oncology. Content independently developed by OncLive.
May 2nd 2024
Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.
Clinical insights on the roles of various members within a multidisciplinary team involved in the care of patients with colorectal cancer.
May 9th 2024
The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.